NCT02359097View on ClinicalTrials.gov

Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 6, 2015

Primary Completion Date

March 12, 2021

Study Completion Date

March 12, 2021

Conditions

Glioblastoma

Interventions

PROCEDURE

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo MRI including DSC or DCE-CBV mapping

DRUG

Ferumoxytol

Given IV

DRUG

Gadoteridol

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI including SS-CBV

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center, Columbus

97239

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT02359097 - Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma | Biotech Hunter | Biotech Hunter